Cargando…
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but prediction of their benefit is challenging. Neoantigens generated through impaired non-mismatch DNA repair may result in greater ICI activity. By analyzing 1,661 ICI-treated patients, we show that deletions and mutations in...
Autores principales: | Hsiehchen, David, Hsieh, Antony, Samstein, Robert M., Lu, Tianshi, Beg, Muhammad S., Gerber, David E., Wang, Tao, Morris, Luc G.T., Zhu, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365618/ https://www.ncbi.nlm.nih.gov/pubmed/32676589 http://dx.doi.org/10.1016/j.xcrm.2020.100034 |
Ejemplares similares
-
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021) -
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018) -
Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
por: Franses, Joseph W, et al.
Publicado: (2022) -
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022) -
Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
por: Hsiehchen, David, et al.
Publicado: (2019)